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Dear Dr Turk
We would like to address some of the issues raised in the recent systematic review, “Early 
prescription opioid use for musculoskeletal disorders and work outcomes: A systematic 
review of the literature” by Carnide et al.1
There are three aspects of our study2 that deserve special comment. First, our study is 
referred to as an historical (e.g., retrospective) cohort study. In fact, this study was a 
prospective cohort study. This study was one of the largest prospective studies ever 
conducted on risk factors related to long term disability following a work-related low back 
injury, and according to the American Academy of Neurology Classification of Evidence 
method, would be considered class 1 evidence for prognostic (risk factor) studies.3 There are 
no RCTs addressing the question of long-term effects of early opioid prescribing after work 
injury and there are unlikely to be such RCTs. Thus, large, prospective cohort studies 
provide the strongest available evidence.
Second, our study included patient-reported measures obtained at baseline (including pain, 
function, recovery expectations, and fear avoidance), which are strong predictors of 
transition to chronic pain following a low back injury.4,5 The ability to control for these 
important covariates is a key methodological issue in assessing association of early opioid 
receipt with subsequent disability. In our study, the impact of adjusting for these important 
baseline factors was substantial; unadjusted risks for disability were 2-3 fold higher.2 A 
similar effect of adjusting for baseline patient self-reported measures was also observed in 
another prospective study.6 Because our study included interviews to collect patient-reported 
measures, Carnide et al1 conclude that the resulting 50% response rate may have led to 
selection bias. There is a tradeoff between only using administrative data which has limited 
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data available for all subjects, but does not have any self-reported information, versus 
conducting patient interviews which include self-reported measures, but not all patients 
participate. We believe it is critical to adjust for pain, function, and key psychosocial risk 
factors when examining the association between early opioid use and work disability.
Third, we adjusted for injury severity based on a review of medical records rather than 
relying solely on administrative claims data. The injury severity rating was completed by 
independent reviewers and was not dependent on patients providing information.
Carnide et al. classified the exposure measurement of 4 of the 5 studies reviewed as having 
high risk for exposure measurement bias because workers may have had opioid prescriptions 
that were not captured by the workers’ compensation data (e.g., paid by another insurer or 
self-paid). In an unpublished study of injured workers using Washington Prescription Drug 
Program data, only 3% of workers with new workers’ compensation claims had an opioid 
prescription in the 3 months prior to the injury and only 1.5% had evidence of chronic 
prescription opioid use prior to the injury. While we agree that the workers’ compensation 
system may not capture all opioid prescriptions, because such a low percentage of workers 
with new WA workers’ compensation claims have recent prescription opioid use prior to 
injury, we believe that there was low or moderate risk rather than high risk of exposure 
measurement bias in our study.
Both the 2016 CDC opioid guideline7 and the 2015 Washington State opioid guideline8 have 
recognized the importance of avoiding unnecessary or ineffective opioid use during the 
acute/subacute pain periods. The Centers for Disease Control and Prevention recommend 
limits for acute prescribing to no more than 3 days in most cases, and no more than seven 
days by exception.7 Ultimate proof of concept, however, should demonstrate that reducing 
unnecessary opioid prescribing for injured workers during the acute/subacute pain periods 
reduces risk of long term disability and improves health outcomes.
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